Cost-utility analysis of panitumumab use compared with cetuximab and bevacizumab for the first-line therapy of wild-type RAS metastatic colorectal cancer in the Peruvian health system.

被引：0
|
作者：
Milton, Valderrama
Apolaya-Segura, Moises
Montenegro, Paola Catherine
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e15171
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15171
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With KRas Wild-Type Tumours in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S264 - S264
  • [42] COST-EFFECTIVENESS ANALYSIS OF PANITUMUMAB PLUS MFOLFOX6 VERSUS BEVACIZUMAB PLUS MFOLFOX6 FOR FIRST-LINE TREATMENT OF PATIENTS WITH WILD-TYPE RAS METASTATIC COLORECTAL CANCER
    Graham, C. N.
    Hechmati, G.
    Hjelmgren, J.
    De Liege, F.
    Lanier, J.
    Knoof, A.
    Knox, H.
    Barber, B.
    de Pouvourville, G.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [43] NICE guidance on cetuximab, bevacizumab, and panitumumab for treatment of metastatic colorectal cancer after first-line chemotherapy
    Rinaldi, Fiona
    George, Elisabeth
    Adler, Amanda I.
    LANCET ONCOLOGY, 2012, 13 (03): : 233 - 234
  • [44] Cetuximab or Panitumumab versus Bevacizumab in the treatment of first line RAS wild type colorectal cancer: pooled analysis of randomized clinical trials.
    Tamburini, Emiliano
    Rudnas, Britt
    Nicolini, Mario
    Nicoletti, Stefania
    Fantini, Manuela
    Ridolfi, Claudio
    Santelmo, Carlotta
    Stocchi, Lucia
    Fabbri, Paolo
    Barzotti, Eleonora
    Drudi, Fabrizio
    Papi, Maximilian
    Gianni, Lorenzo
    Tassinari, Davide
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [46] COST-EFFECTIVENESS OF BEVACIZUMAB VERSUS CETUXIMAB VERSUS PANITUMUMAB COMBINED WITH FIRST-LINE FOLFOX FOR METASTATIC COLORECTAL CANCER IN BRAZIL
    Sasse, Andre
    Carvalho, Adriana
    ANNALS OF ONCOLOGY, 2012, 23 : 100 - 100
  • [47] COST-UTILITY EVALUATION OF THE USE OF CETUXIMAB AS LAST LINE FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER
    Croci, A.
    Aleman, A.
    Perez Galan, A.
    VALUE IN HEALTH, 2015, 18 (07) : A823 - A823
  • [48] A COST-EFFECTIVENESS ANALYSIS (CEA) OF CETUXIMAB plus FOLFIRI COMPARED TO BEVACIZUMAB plus FOLFIRI AS FIRST-LINE TREATMENT OF RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC): A US ANALYSIS BASED ON LOCATION OF PRIMARY TUMOR
    Evans, R.
    Aggarwal, H.
    Takundwa, R.
    Chin, S.
    Fenwick, E.
    VALUE IN HEALTH, 2018, 21 : S31 - S31
  • [49] Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer
    Wong, W. W. L.
    Zargar, M.
    Berry, S. R.
    Ko, Y. J.
    Riesco-Martinez, M.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2019, 26 (05) : E597 - E609
  • [50] Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Rivera, Fernando
    Valladares, Manuel
    Gea, Salvador
    Lopez-Martinez, Noemi
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (06) : 574 - 584
12345